Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients

• DOI: 10.1186/s12885-021-08070-6
• Publication Date: 2021-04-06T19:03:01Z
• Authors: Sara Ribeirinho-S...; Diana Pádua; Ana Luísa Amaral; Elvia Valentini; Daniela Azevedo; Cristiana Marques; Rita Barros; Filipa Macedo; Patrícia Mesquita; Raquel Almeida
• Keywords: CDX2; Surgical oncology

Abstract Background Colorectal cancer (CRC) remains a serious health concern worldwide. Despite advances in diagnosis and treatment, about 15 to 30% of stage II CRC patients subjected tumor resection with curative intent, develop disease relapse. Moreover, the therapeutic strategy adopted after surgery is not consensual for these patients. This supports imperative need find new prognostic predictive biomarkers CRC. Methods For this purpose, we used one-hospital series 227 patient samples assess biomarker potential immunohistochemical expression MUC2 mucin CDX2 SOX2 transcription factors. The Kaplan-Meier method was generate disease-free survival curves that were compared using log-rank test, order determine prognosis cases different proteins, mismatch repair (MMR) status administration or adjuvant chemotherapy. Results In series, none studied showed value outcome. However low MUC2, high CDX2, absence MMR-proficiency, conferred significantly worst prognosis. clear benefit from treatment Conclusion conclusion, observe respond better when treated observation involved resistance fluorouracil-based chemotherapy might be promising future